All targets
Target workspace
5α-reductase
Converts testosterone to dihydrotestosterone.
Pathway & druggability
Androgen metabolism
Druggability: High (finasteride approved)
Evidence behind this
Confidence score95%
Signal strength: HighLevel 1 (RCT + regulatory approval)
Evidence grade
Approved
Reduced prostate volume, improved symptom scores vs placebo.
Mechanism
DHT reduction decreases prostate volume and improves urinary flow.
clinical trialfda labelPhase III
Authoritative sources
AI-generated summary
Generated March 15, 2026Last verified June 24, 2026
Finasteride is FDA-approved for BPH with Phase III PLESS trial evidence demonstrating symptom and volume benefits. 5α-reductase mechanism directly addresses disease pathophysiology.
Source papers
- McConnell JD et al., NEJM 1993
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.